Press Releases

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Filter Releases
 
Feb 19, 2013
Porton Down, UK; February 19 2013: GW Pharmaceuticals plc (AIM:GWP) today announces the appointment of Cabot Brown as a non-executive director with immediate effect. Mr Brown will sit on the Nominations Committee, Audit Committee, as well as the Remuneration Committee. Cabot Brown, aged 51, has more than 30 years of expe...
Nov 28, 2012
Porton Down, UK; November 28 2012: GW Pharmaceuticals plc (AIM:GWP) reports results from a Phase IIa exploratory study which has identified GW’s novel cannabinoid, GWP42004, as a potential new oral treatment for type 2 diabetes. In the study, which examined a number of clinically relevant endpoints in patients with type 2 diabetes, GWP4200...
Nov 27, 2012
Porton Down, UK, 28 November 2012: GW Pharmaceuticals plc (AIM: GWP, “GW” or “the Group”), the specialty pharmaceutical company focused on cannabinoid science, announces its preliminary results for the year ended 30 September 2012. COMMERCIAL: Sativex in-market sa...
Nov 12, 2012
Porton Down, UK; 12 November 2012: GW Pharmaceuticals plc (AIM: GWP) today announces that its Managing Director, Justin Gover will be presenting at the Lazard Capital Markets 9th Annual Healthcare Conference in New York on Tuesday, 13 November 2012 at 11.30am EST (4.30pm GMT). A live webcast will be accessible via the investor relations section ...
Oct 12, 2012
that results of the MObility ImproVEments with Spasticity in Multiple Sclerosis (MOVE) 2 observational study performed in Germany, with 300 patients, showed that one month’s treatment with Sativex® (THC:CBD) oromucosal spray reduces moderate to severe multiple sclerosis spasticity (MSS) by 20% or more in 4 out of 10 patients previousl...
Oct 1, 2012
London, UK; October 1st 2012: GW Pharmaceuticals plc (AIM: GWP) today announces the appointment, effective today, of Christopher John Tovey to the newly created position of Chief Operating Officer.Chris, aged 47, joins GW having gained a wealth of commercial experience from more ...
Sep 13, 2012
London, UK; 13 September 2012 GW pharmaceuticals (LSE:GWP “GW”) is pleased to note the University of Reading’s press release, reproduced below, announcing the publication in the peer-reviewed journal The British Journal of Pharmacology (1) of promising data from studies on cannabidivarin (CBDV), a largely ignored natural compo...
Jun 22, 2012
Porton Down, UK, 21 June 2012: GW Pharmaceuticals plc (AIM: GWP, “GW” or “the Group”), the specialty pharmaceutical company focused on cannabinoid science, is pleased to note the announcement from its partner Almirall that the resolution of the German Federal Joint Committee (G-BA) on the early evaluation of benefits for ...
May 22, 2012
Porton Down, UK, 22 May 2012: GW Pharmaceuticals plc (AIM: GWP, “GW” or “the Group”), the specialty pharmaceutical company focused on cannabinoid science, announces its interim results for the six months ended 31 March 2012.COMMERCIAL: STRONG PROGRESSSativex...
May 22, 2012
GW’s cancer pain clinical programme is being wholly funded by Otsuka Pharmaceutical Co. Ltd, which has licensed the US commercialisation rights to this product. The trials are designed to obtain approval in this indication from the Food & Drug Administration (FDA) in the US, and these data will also be used by GW f...
May 15, 2012
Porton Down, UK; 15 March 2012: GW Pharmaceuticals plc (AIM: GWP) announces that it has signed an amendment to its Sativex® licence agreement with Almirall S.A. As part of the revised agreement, Almirall has been granted rights to market Sativex® in Mexico and GW will receive a new near term milestone payment of €12 million (...
May 8, 2012
HIGHLIGHTS• Sativex® is already available in the UK, Spain, Germany and Denmark. Launches currently in preparation in Italy, Sweden, Austria and Czech Republic• Recommendation for approval now received in Belgium, Fi...
Apr 23, 2012
This Phase IIb study was the first major trial carried out by GW and Otsuka Pharmaceutical as part of the development program aimed at securing regulatory approval for Sativex®from the Food & Drug Administration (FDA) in the United States. Top line results from this study were originally reported in March 2010 and a Phase III tr...
Apr 16, 2012
Porton Down, UK; 16 April 2012: GW Pharmaceuticals plc (AIM: GWP) confirms that it has now earned the €11.9 million milestone payment due as a result of the recently amended terms of its licence agreement with Almirall S.A. (announced on 15 March 2012). This milestone reflects the revised terms of the expanded collaboration between GW and ...
Mar 8, 2012
Porton Down, UK; 8 March 2012: GW Pharmaceuticals plc (AIM: GWP) today announces that, effective March 1st 2012, Professor Vincenzo Di Marzo has agreed to direct GW’s global pre-clinical research programme and will assume the title of Research Director of GW Research Ltd and GW’s Cannabinoid Research Institute....
= add release to Briefcase

Ways to keep up to date with GW